Mehwish Shafiq*, Muqaddas Rana and Shahnaz Chaudhary
Human cells produce an enormous number of proteins and dysfunction in these may lead to serious diseases and developmental abnormalities. To treat these protein de iciencies the missing or dysfunctional molecules are complemented or substituted with therapeutics provided by different biological systems. However, protein therapeutics must unavoidably adhere to quality constraints that are much stricter than those for chemical industries. Although it is undoubtedly a challenging task to obtain an active protein in a way that is economically feasible, biopharmaceuticals (recombinant proteins, monoclonal antibodies or vaccines) are the largest group of drugs developed in the pharmaceutical industry. Market calculations estimated the recombinant protein drug industry to be around 10% of the entire drug market, predicting an even larger proportion in the future. The global market of biopharmaceuticals is estimated to grow at a Compound Annual Growth Rate (CAGR) of 13.8% from 2018 to 2025, according to the latest report developed by allied market research. The report biopharmaceuticals market by type and application: Global opportunity analysis and industry forecast, presenting an analysis of pro iles of the major player projects that the global biopharmaceuticals market, which reached $186,470 million in 2017, will have reached $526,008 million by 2025. The more detailed characteristics of the expected value growth of particular biologic types in the biopharmaceuticals market (divided into dominating monoclonal antibody, growth and coagulation factor, interferon, vaccine, insulin, erythropoietin and hormone) are available in the report and on the allied market research website.
HTML PDFShare this article
